×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARWR – arrowhead pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARWR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/2
08:04 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $80.00 to $85.00. They now have a "buy" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $80.00 to $85.00. They now have a "buy" rating on the stock.
12/2
07:30 am
arwr
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Low
Report
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
12/1
04:00 pm
arwr
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
Low
Report
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
12/1
11:42 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $42.00 to $62.00. They now have a "buy" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $42.00 to $62.00. They now have a "buy" rating on the stock.
12/1
08:09 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
11/27
07:46 pm
arwr
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript [Seeking Alpha]
Medium
Report
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript [Seeking Alpha]
11/27
11:01 am
arwr
Arrowhead: Gains Make Mockery Of My Sell Call - But Jury May Still Be Out (Rating Upgrade) [Seeking Alpha]
Medium
Report
Arrowhead: Gains Make Mockery Of My Sell Call - But Jury May Still Be Out (Rating Upgrade) [Seeking Alpha]
11/27
01:29 am
arwr
Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/25/2025
04:00 pm
ARWR
arrowhead pharmaceuticals, inc.
MISS
Report
23.3%
arrowhead pharmaceuticals, inc.
8/7/2025
04:01 pm
ARWR
arrowhead pharmaceuticals, inc.
MISS
Report
2.2%
arrowhead pharmaceuticals, inc.
5/12/2025
04:01 pm
ARWR
arrowhead pharmaceuticals, inc.
BEAT
Report
9.4%
arrowhead pharmaceuticals, inc.
2/10/2025
04:01 pm
ARWR
arrowhead pharmaceuticals, inc.
MISS
Report
-5.2%
arrowhead pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/5
04:01 pm
arwr
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: PERRY MICHAEL S
Low
Report
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: PERRY MICHAEL S
12/1
06:10 pm
arwr
Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 28 Filed by: Ferrari Mauro
Medium
Report
Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 28 Filed by: Ferrari Mauro
11/28
01:20 pm
arwr
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: Ferrari Mauro
Neutral
Report
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: Ferrari Mauro
11/25
04:14 pm
arwr
Form 10-K ARROWHEAD PHARMACEUTICAL For: Sep 30
High
Report
Form 10-K ARROWHEAD PHARMACEUTICAL For: Sep 30
11/25
04:11 pm
arwr
Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25
High
Report
Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25
11/18
02:50 pm
arwr
Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 18
Medium
Report
Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 18
10/10
04:03 pm
arwr
Form 10-K/A ARROWHEAD PHARMACEUTICAL For: Sep 30
Low
Report
Form 10-K/A ARROWHEAD PHARMACEUTICAL For: Sep 30
10/3
06:15 pm
arwr
Form 4 ARROWHEAD PHARMACEUTICAL For: Oct 01 Filed by: Hamilton James C
Medium
Report
Form 4 ARROWHEAD PHARMACEUTICAL For: Oct 01 Filed by: Hamilton James C
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Mammoth Energy, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm
23.9%
11/25 Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25 19.2%
12/2 Form 424B5 ARROWHEAD PHARMACEUTICAL 12.5%
3/19 Form 8-K ARROWHEAD PHARMACEUTICAL For: Mar 14 9.3%
11/25 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. 8.8%
8/5 Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 05 6.8%
4/20 Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks [Yahoo! Finance News] 6.4%
11/7 Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 05 Filed by: Myszkowski Kenneth Allen 6.3%
5/8 Q2/2019 3/31/2019 EPS 0.240 ZacksConsensus 0.220 ActVsEst 0.020 - Beat 6.1%
8/19 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at B. Riley from $32.00 to $46.00. They now have a "buy" rating on the stock. 5.4%
11/25 Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25 19.2%
12/2 Form 424B5 ARROWHEAD PHARMACEUTICAL 12.5%
3/19 Form 8-K ARROWHEAD PHARMACEUTICAL For: Mar 14 9.3%
11/25 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. 8.8%
8/5 Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 05 6.8%
4/20 Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks [Yahoo! Finance News] 6.4%
11/7 Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 05 Filed by: Myszkowski Kenneth Allen 6.3%
5/8 Q2/2019 3/31/2019 EPS 0.240 ZacksConsensus 0.220 ActVsEst 0.020 - Beat 6.1%
8/19 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at B. Riley from $32.00 to $46.00. They now have a "buy" rating on the stock. 5.4%
TOP News Decliners
3/15
Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Salary Justified? [Yahoo! Finance News]
-16.8%
2/6 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at Cantor Fitzgerald from $50.00 to $55.00. They now have a "neutral" rating on the stock. -13.5%
12/2 3 Soaring Biotech Stocks to Watch in December [The Motley Fool] -13.3%
1/21 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is now covered by analysts at Svb Leerink Llc. They set an "underperform" rating and a $32.00 price target on the stock. -10.5%
3/9 Why Arrowhead Pharmaceuticals Shares Dropped 15% in February [The Motley Fool] -7.5%
4/29 Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 27 Filed by: GIVEN BRUCE D -7.4%
10/23 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was given a new $46.00 price target on by analysts at B. Riley. They now have a "buy" rating on the stock. -7.0%
8/22 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -6.9%
6/27 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. -6.8%
12/20 Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease -6.6%
2/6 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at Cantor Fitzgerald from $50.00 to $55.00. They now have a "neutral" rating on the stock. -13.5%
12/2 3 Soaring Biotech Stocks to Watch in December [The Motley Fool] -13.3%
1/21 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is now covered by analysts at Svb Leerink Llc. They set an "underperform" rating and a $32.00 price target on the stock. -10.5%
3/9 Why Arrowhead Pharmaceuticals Shares Dropped 15% in February [The Motley Fool] -7.5%
4/29 Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 27 Filed by: GIVEN BRUCE D -7.4%
10/23 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was given a new $46.00 price target on by analysts at B. Riley. They now have a "buy" rating on the stock. -7.0%
8/22 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -6.9%
6/27 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. -6.8%
12/20 Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease -6.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: